What is Oralucent?
Oralucent operates at the intersection of consumer health and advanced dental technology. The company specializes in the development of innovative oral care solutions, most notably its flagship electric light therapy toothbrush. By integrating blue and red light therapy, the device is engineered to target bacteria, mitigate gum inflammation, and facilitate teeth whitening. This clinical-grade approach to daily hygiene has earned the trust of dental professionals, establishing Oralucent as a key player in the preventative dental care landscape. Their product ecosystem, which includes specialized whitening gels and hygiene accessories, addresses the growing consumer demand for non-invasive, high-efficacy dental wellness tools.
How much funding has Oralucent raised?
Oralucent has raised a total of $539K across 2 funding rounds:
Debt
$19K
Debt
$520K
Debt (2021): $19K with participation from PPP
Debt (2026): $520K, investors not publicly disclosed
Key Investors in Oralucent
Undisclosed Investor
A private capital provider specializing in debt financing and strategic growth initiatives for health-tech enterprises.
PPP
Public-Private Partnership
Undisclosed Investor
An institutional investor participating in the funding round to support the long-term scaling of innovative dental technology.
What's next for Oralucent?
With the infusion of $520K, Oralucent is poised to accelerate its enterprise-level expansion. The strategic allocation of this capital will likely focus on scaling manufacturing capabilities to meet rising demand and deepening its penetration into professional dental networks. As the company transitions into a more mature phase of its lifecycle, the focus will shift toward clinical validation and market diversification. By maintaining its commitment to evidence-based oral health solutions, Oralucent is well-positioned to disrupt traditional dental care paradigms and capture a larger share of the global wellness market.
See full Oralucent company page
